Navigation Links
MiMedx Announces Brian J. Splan as President
Date:3/3/2008

TAMPA, Fla., March 3 /PRNewswire/ -- MiMedx, Inc., a development-stage medical device company, announced today that Brian J. Splan has been appointed President. In this role, Mr. Splan will be providing strategic and tactical leadership to the MiMedx team.

Throughout his 34-year career, Mr. Splan has consistently demonstrated the ability to manage a wide range of operations and deliver excellent results for customers and shareholders. Beginning in 1986, Mr. Splan was employed by Smith & Nephew, Inc. in a variety of positions of increasing responsibility. Mr. Splan was Executive Vice President of Finance and Administration of Smith & Nephew, Inc., President of Ioptex Research, Inc., a subsidiary of Smith & Nephew, PLC. He also served as President of the Healthcare Division of Smith & Nephew, Inc. US operations.

"We are delighted to have the opportunity to add someone of Brian's caliber to our senior management team," said Tom D'Alonzo, CEO of MiMedx. "His extensive experience will help us to accelerate our exciting discoveries into product candidates."

MiMedx recently became a public Company through a reverse merger with Alynx, Co. For more information on MiMedx, see http://www.mimedx.com.

About MiMedx, Inc.

Founded in 2006, MiMedx, Inc. is a development-stage Florida corporation with technology focusing on biomaterials for soft tissue repair, such as tendons, ligaments and cartilage, as well as other biomaterial-based products for other medical applications. The company, based in Tampa, Florida, holds an exclusive, worldwide license from the Shriner's Hospital for Children and the University of South Florida Research Foundation for certain nordihydroguaiaretic acid (NDGA) technology. MiMedx is targeting this proprietary technology for a number of diverse medical applications.

MiMedx, Inc. also has a wholly-owned subsidiary, SpineMedica, LLC, based in Atlanta, Georgia,
'/>"/>

SOURCE MiMedx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
2. Boston Scientific Announces European Approval of New Heart Failure Lead
3. WaferGen Announces Management Team Promotions
4. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
5. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
6. DW Healthcare Partners Announces the Sale of Tandem Labs
7. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
8. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
9. MarketResearch.com Announces Distribution of Spectra Intelligence Research
10. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
11. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Vermillion, Inc. (Nasdaq:   VRML), a ... today that investors including Oracle Investment Management, ... several Vermillion directors have agreed to purchase approximately ... stock and warrants to purchase unregistered shares of ... Under the terms of the private ...
(Date:12/24/2014)... LOUIS , Dec. 23, 2014 ... today that the waiting period under the Hart-Scott-Rodino ... the acquisition expired on December 22, 2014, thereby ... review requirement for the acquisition of the Company ... U.S. antitrust clearance satisfies another condition to closing ...
(Date:12/24/2014)... , Dec. 23, 2014  NeuroLifeSciences announced today ... in children with attention deficit/hyperactivity disorder published in ... The paper, titled "Pilot Phase 2 ... ( Konofal et al, Drug Des Devel ... shows that mazindol might be an effective, well-tolerated, ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... 16 Regado Biosciences, a privately held company leading ... announced that David J. Mazzo, PhD, President and CEO, ... Conference.  Dr. Mazzo,s presentation will be given at the ... September 22, 2010 at 8:00 a.m. EDT in Ballroom ...
... DENVER, Sept. 16 BioSpace and BioMed ... BioMed Central Career Network today, ... professionals seeking quality recruitment, job opportunities and ... ) (Logo: http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO ) ...
... (NYSE: CRY ), an implantable biological medical device ... participate in the UBS Global Life Sciences Conference at The ... Ashley Lee, executive vice president, chief operating officer and chief ... on Tuesday, September 21, 2010 at 3:30 p.m., Eastern Time. ...
Cached Biology Technology:Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City 2Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City 3BioSpace and BioMed Central Create Global Career Community 2CryoLife to Present at UBS Global Life Sciences Conference 2
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security ... 3.6% from 2014 to 2019. Although the U.S. market ... Canada is expected to grow at a ...
(Date:12/17/2014)... 2014  HITLAB SM announced today its ... to confirm its adherence to current U.S. Food ... HITLAB to conduct regulated smart device and smart ... patient safety and research quality. "HITLAB ... and delivery with innovative technology," said Laura ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... (NTU) and Temasek Foundation are working together to ... People,s Republic of China which are prone to ... seismic-resistant construction technologies, the programme aims to promote ... enhance the skills of those involved in China ...
... -- Researchers at Burnham Institute for Medical Research ... University of Maryland have demonstrated that an enzyme ... targeted to kill dangerous pathogens. In addition, investigators ... and suppress the growth of pathogenic bacteria. These ...
... University has succeeded in extracting long DNA fragments from ... Linnaeus, apprentice Adam Afzelius. It is hoped that the ... light on whether plants growing today at Linnaeus, Hammarby ... himself. A large number of plants of uncertain ...
Cached Biology News:NTU and Temasek Foundation transfer technology knowhow to China's quake-prone regions 2NTU and Temasek Foundation transfer technology knowhow to China's quake-prone regions 3The path to new antibiotics 2
... General description: Designed for use with ... CLS number is a new product number, ... If showing no availability yet, please order ... contact customer service for assistance. Comp Dim: ...
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
... Stem Cell Identification Kit. ... a substrate for the ... that is highly expressed ... cells, making ALDH an ...
... LED produces output at 470 nm; includes interface ... S2000 or installed into rack or desktop boxes ... Source is an LED that produces either pulsed ... blue region -- for fluorescence measurements. The source ...
Biology Products: